` JAGX (Jaguar Health Inc) vs S&P 500 Comparison - Alpha Spread

JAGX
vs
S&P 500

Over the past 12 months, JAGX has underperformed S&P 500, delivering a return of -96% compared to the S&P 500's 8% growth.

Stocks Performance
JAGX vs S&P 500

Loading
JAGX
S&P 500
Add Stock

Performance Gap
JAGX vs S&P 500

Loading
JAGX
S&P 500
Difference

Performance By Year
JAGX vs S&P 500

Loading
JAGX
S&P 500
Add Stock

Competitors Performance
Jaguar Health Inc vs Peers

S&P 500
JAGX
LLY
JNJ
NOVO B
ROG
Add Stock

Jaguar Health Inc
Glance View

Market Cap
7.1m USD
Industry
Pharmaceuticals

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 52 full-time employees. The company went IPO on 2015-05-13. The firm is focused on developing plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea. The firm operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. Its Canalevia-CA1 is used for chemotherapy-induced diarrhea in dogs. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. Its wholly owned subsidiary is Napo Pharmaceuticals, Inc.

JAGX Intrinsic Value
54.179 USD
Undervaluation 80%
Intrinsic Value
Price
Back to Top